.
MergerLinks Header Logo

Announced

Viscient Biosciences offered to merge with Organovo.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Pending

Acquisition

Friendly

clinical laboratories

Merger

Single Bidder

biotechnology company

Biotechnology

Majority

Public

Synopsis

Edit

Viscient Biosciences, a San Diego-based biotechnology company, offered to merge with Organovo, an early-stage medical laboratory and research company. Financial terms were not disclosed. "There remains tremendous opportunity to unlock the power of Organovo's proprietary technology. Viscient has built a powerful NASH drug discovery platform to a value of tens of millions of dollars in a very short period of time, with strong internal efforts coupled with contract research performed by Organovo. Having already established the paradigm for drug discovery in 3D tissue in liver, Viscient now has the potential to efficiently use the other tissues in Organovo's portfolio to develop drugs for additional high-value indications. After reviewing the recent deal landscape, it is clear to me that a Viscient/Organovo combined entity could be valued in the hundreds of millions over the next couple of years as we hit preclinical and clinical milestones for drug candidates, unlocking significant value for all stakeholders." Keith Murphy, CEO, Viscient Biosciences.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US